bioengineer.org /2 weeks ago

Anti-CGRP Migraine Drugs Cut Monthly Headache Days by Nearly Half in Catalan Cohort

A Catalan registry study of 5438 patients found anti-CGRP antibody treatment cut monthly migraine days by about 45 percent while spending surpassed 18 million euros.

Read source
moneytalksnews.com /1 month ago

New Migraine Guidelines Expand Treatment Options: Here’s Your Guide

Preventive care now may begin at four migraine days a month, with newer CGRP drugs joining older medicines as first-line options

Read source
healio.com /1 week ago

ANGPTL4 inhibition appears to reduce triglycerides

CHICAGO — A monoclonal antibody that inhibits angiopoietin-like protein 4 was linked to triglyceride reduction at 12 weeks in adults with high triglycerides, researchers reported a...

Read source
qchron.com /4 weeks ago

Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Genera...

The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China

Read source
pharmexec.com /6 days ago

<![CDATA[FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated wit...

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease]]>

Read source
healio.com /1 month ago

Subcutaneous risankizumab exhibits ‘high efficacy’ in Crohn’s

NASHVILLE, Tenn. — Patients with Crohn’s disease achieved significantly higher clinical remission and endoscopic response rates at week 12 with subcutaneous risankizumab induction...

Read source
biopharmadive.com /1 month ago

Argenx falls as Sjögren’s setback offsets celiac drug progress

A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart. 

Read source
biopharmadive.com /1 month ago

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.

Read source
cafepharma.com /2 weeks ago

Argenx

Argenx Anonymous (not verified) Thu, 11/05/2026 - 18:31 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Read source
cafepharma.com /1 month ago

Argenx

Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Read source
qchron.com /1 week ago

PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FD...

PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor respo...

Read source
healio.com /4 weeks ago

The FDA has expanded its approval of Skyrizi to include subcutaneous induction for adults with moderately to severely ac...

The FDA has expanded its approval of Skyrizi to include subcutaneous induction for adults with moderately to severely active Crohn’s disease.Risankizumab (Skyrizi, AbbVie) was appr...

Read source
painnewsnetwork.org /1 month ago

Wearable Device Predicts Migraines With Over 90% Accuracy

By Pat AnsonImagine what it would be like to know – with over 90% accuracy – that you’re going to have a migraine tomorrow.You’d be able to plan ahead. Change your schedule. Get ex...

Read source
qchron.com /1 week ago

Antengene Presents Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Nov. 11, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ded...

Read source
bioengineer.org /1 month ago

Prefilled Syringe Delivers Autoimmune Drug Efgartigimod as Fast and Effectively as the Vial

For millions of people living with IgG-mediated autoimmune diseases such as generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)...

Read source
biopharmadive.com /6 days ago

CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares. 

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.